{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-019277","form_type":"8-K","ticker":"COCH","cik":"0001840877","company_name":"Envoy Medical, Inc.","filed_at":"2024-03-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.914228+00:00","generated_at":"2026-06-05T04:59:37.736730+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Envoy Medical secures up to $10M debt from Glen Taylor for Acclaim cochlear implant trial","bullets":["Up to $10M five-year unsecured facility from board member/controlling stockholder Glen Taylor; initial draw of $5M.","8% interest, compounding first two years; warrants for 500k shares at $1.24/share issued for initial draw.","Proceeds will fund US pivotal clinical trial for fully implanted Acclaim cochlear implant (FDA Breakthrough Designation).","Interest accrues first two years, paid quarterly thereafter; no conversion rights.","Remaining $5M available in $2.5M tranches until February 2029 upon meeting conditions."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-019277","json":"https://secwatch.observer/filing/0001213900-24-019277.json","markdown":"https://secwatch.observer/filing/0001213900-24-019277.md","text":"https://secwatch.observer/filing/0001213900-24-019277.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840877/000121390024019277/0001213900-24-019277-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840877/000121390024019277/ea0201093-8k_envoy.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T04:59:37.736730+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bff4d506ecabfcefa3d4287d411987e507a1e025","claim":"Envoy Medical, Inc. incurred loan of up to $10,000,000 with GAT Funding, LLC at 8.0% per annum maturing 2029-02-27.","evidence_excerpt":"a Material Definitive Agreement Envoy Medical, Inc. (the “Company”) has issued a promissory note, effective as of February 27, 2024 (the “Note”) with a principal amount of up to $10,000,000 to GAT Funding, LLC (“GAT”), an entity controlled by Glen Taylor, who is a member of the Company’s board of directors and controlling stockholder of the Company. Upon meeting","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840877/000121390024019277/0001213900-24-019277-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"loan"},{"label":"Principal","value":"up to $10,000,000"},{"label":"Counterparty","value":"GAT Funding, LLC"},{"label":"Rate","value":"8.0% per annum"},{"label":"Maturity","value":"2029-02-27"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"3b5221f3c55aade8b61763b14865992b6e17beef","claim":"Envoy Medical, Inc. entered into Note with GAT Funding, LLC valued at principal amount of up to $10,000,000 (effective 2024-02-27).","evidence_excerpt":"Envoy Medical, Inc. (the “Company”) has issued a promissory note, effective as of February 27, 2024 (the “Note”) with a principal amount of up to $10,000,000 to GAT Funding, LLC (“GAT”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840877/000121390024019277/0001213900-24-019277-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"GAT Funding, LLC"},{"label":"Value","value":"principal amount of up to $10,000,000"},{"label":"Effective","value":"2024-02-27"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}